Press coverage about PharmAthene (NYSE:PIP) has trended somewhat positive on Thursday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. PharmAthene earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned media headlines about the financial services provider an impact score of 47.1392258274329 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of PharmAthene (PIP) opened at 0.65 on Thursday. PharmAthene has a 12-month low of $0.47 and a 12-month high of $3.50. The company has a 50 day moving average of $0.77 and a 200-day moving average of $2.08.
TRADEMARK VIOLATION WARNING: This piece was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/09/21/pharmathene-pip-getting-somewhat-positive-news-coverage-report-shows.html.
Pharmathene, Inc (Pharmathene) is a biodefense company. The Company is focused on the development of medical counter measures against biological and chemical threats. The Company is involved in the development of two next generation anthrax vaccines. The Company’s anthrax vaccines use recombinant protective antigen (rPA) manufacturing processes.
Receive News & Ratings for PharmAthene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmAthene Inc. and related companies with MarketBeat.com's FREE daily email newsletter.